Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 15, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-07-08
DOI
10.1186/s13045-022-01310-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies
- (2022) Eman A. Abd El-Meguid et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Stabilization of PIM Kinases in Hypoxia Is Mediated by the Deubiquitinase USP28
- (2022) Rachel K. Toth et al. Cells
- In Vitro Anticancer Activity Screening of Novel Fused Thiophene Derivatives as VEGFR-2/AKT Dual Inhibitors and Apoptosis Inducers
- (2022) Rana M. Abdelnaby et al. Pharmaceuticals
- Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update
- (2021) Robert Roskoski PHARMACOLOGICAL RESEARCH
- ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma
- (2021) Prateek Khanna et al. Science Translational Medicine
- Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia
- (2021) Kalpana K. Bhanumathy et al. Cancers
- Small-Molecule Drug Discovery in Triple Negative Breast Cancer: Current Situation and Future Directions
- (2021) Minru Liao et al. JOURNAL OF MEDICINAL CHEMISTRY
- The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab
- (2021) Bruno Carvalho et al. Scientific Reports
- Design, synthesis and biological evaluation of dual HDAC and VEGFR inhibitors as multitargeted anticancer agents
- (2021) Xia Xue et al. INVESTIGATIONAL NEW DRUGS
- Targeting Autophagy-Related Epigenetic Regulators for Cancer Drug Discovery
- (2021) Yang Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery, Synthesis, and Evaluation of Highly Selective Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Inhibitor for the Potential Treatment of Metastatic Triple-Negative Breast Cancer
- (2021) Yang Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Interactions between Ligand-Bound EGFR and VEGFR2
- (2021) Michael D. Paul et al. JOURNAL OF MOLECULAR BIOLOGY
- EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives
- (2021) Ahmed A.E. Mourad et al. LIFE SCIENCES
- Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2
- (2021) Szu Lee et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Dual target inhibitors based on EGFR: Promising anticancer agents for the treatment of cancers (2017-)
- (2021) Liping Hu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- DYRK1A inhibitors for disease therapy: Current status and perspectives
- (2021) Tong Liu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- VEGFa/VEGFR2 autocrine and paracrine signaling promotes cervical carcinogenesis via β-catenin and snail
- (2021) Chandra Bhushan Prasad et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Antitumoral effects of dovitinib in triple-negative breast cancer are synergized by calcitriol in vivo and in vitro
- (2021) Janice García-Quiroz et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Design, synthesis, and molecular docking of novel 2‐arylbenzothiazole multiangiokinase inhibitors targeting breast cancer
- (2020) Heba T. Abdel‐Mohsen et al. ARCHIV DER PHARMAZIE
- Uses of cyclohexane-1,3-dione for the synthesis of 1,2,4-triazine derivatives as anti-proliferative agents and tyrosine kinases inhibitors
- (2020) Nadia Y. Megally Abdo et al. BIOORGANIC CHEMISTRY
- Evolution of Systemic Therapy for Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. HEPATOLOGY
- Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)
- (2020) Shota Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology
- (2020) Marialuisa Moccia et al. JOURNAL OF MEDICINAL CHEMISTRY
- Experimental and Computational Approaches to Improve Binding Affinity in Chemical Biology and Drug Discovery
- (2020) Anuraj Nayarisseri CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Research Progress of Small Molecule VEGFR/c-Met Inhibitors as Anticancer Agents (2016–Present)
- (2020) Qian Zhang et al. MOLECULES
- Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2
- (2020) Frangky Sangande et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- New insights into the role of co-receptor neuropilins in tumour angiogenesis and lymphangiogenesis and targeted therapy strategies
- (2020) Lin Zhao et al. JOURNAL OF DRUG TARGETING
- Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment
- (2020) Xiaopeng Peng et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Enhancing anti-tumour efficacy with immunotherapy combinations
- (2020) Funda Meric-Bernstam et al. LANCET
- NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors
- (2020) Romel Somwar et al. Communications Biology
- Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities
- (2019) Chelsea C. Estrada et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Targeting Alterations in the RAF–MEK Pathway
- (2019) Rona Yaeger et al. Cancer Discovery
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pan-TAM tyrosine kinase inhibitor BMS-777607 enhances anti-PD-1 mAb efficacy in a murine model of triple-negative breast cancer
- (2019) Canan Kasikara et al. CANCER RESEARCH
- Design, synthesis and evaluation of sulfonylurea-containing 4-phenoxyquinolines as highly selective c-Met kinase inhibitors
- (2019) Xiang Nan et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer
- (2019) Elizabeth Won et al. CLINICAL CANCER RESEARCH
- Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization
- (2019) Masashi Iwamoto et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Multiscale modeling reveals angiogenesis-induced drug resistance in brain tumors and predicts a synergistic drug combination targeting EGFR and VEGFR pathways
- (2019) Weishan Liang et al. BMC BIOINFORMATICS
- The VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers
- (2019) Razelle Kurzrock et al. CLINICAL CANCER RESEARCH
- 2,7-naphthyridinone-based MET kinase inhibitors: A promising novel scaffold for antitumor drug development
- (2019) Lin-Sheng Zhuo et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Advancing Drug Discovery via Artificial Intelligence
- (2019) H.C. Stephen Chan et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Dual VEGFR-2/PIM-1 kinase inhibition towards surmounting the resistance to antiangiogenic agents via hybrid pyridine and thienopyridine-based scaffolds: Design, synthesis and biological evaluation
- (2019) Ola H. Rizk et al. BIOORGANIC CHEMISTRY
- Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study
- (2019) Rina Hui et al. CLINICAL CANCER RESEARCH
- Anti-VEGF/VEGFR2 monoclonal antibodies and their combinations with PD-1/PD-L1 inhibitors in clinic
- (2019) Feng Gao et al. CURRENT CANCER DRUG TARGETS
- Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors
- (2019) Heba T. Abdel-Mohsen et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors
- (2019) Huiqiang Wei et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- RAF Kinase Inhibitor Protein in Myeloid Leukemogenesis
- (2019) Armin Zebisch et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Brivanib Exhibits Potential for Pharmacokinetic Drug–Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes
- (2019) Jakub Hofman et al. MOLECULAR PHARMACEUTICS
- Synthesis and biological evaluation of new MET inhibitors with 1,6-naphthyridinone scaffold
- (2019) Ming-Shu Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Quinolizidine alkaloids derivatives from Sophora alopecuroides Linn: Bioactivities, structure-activity relationships and preliminary molecular mechanisms
- (2019) Yang Li et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- The Taxonomy of Covalent Inhibitors
- (2018) Alfred Tuley et al. BIOCHEMISTRY
- Synthesis and biological evaluation of 4,6-diaryl-2-pyrimidinamine derivatives as anti-breast cancer agents
- (2018) Linyi Liu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
- (2018) Jorge E. Cortes et al. BLOOD
- Synthesis and bioevaluation and doking study of 1 H -pyrrolo[2,3- b ]pyridine derivatives bearing aromatic hydrazone moiety as c-Met inhibitors
- (2018) Wenhui Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Structure-activity relationships of 2, 4-disubstituted pyrimidines as dual ERα/VEGFR-2 ligands with anti-breast cancer activity
- (2018) Guoshun Luo et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Design, synthesis and biological evaluation of a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors
- (2018) Manman Wei et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Design, synthesis, biological evaluation and molecular modeling of novel 1 H -pyrazolo[3,4-d]pyrimidine derivatives as BRAF V600E and VEGFR-2 dual inhibitors
- (2018) Yuanyuan Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy?
- (2018) Delia De Lisi et al. Expert Opinion on Drug Metabolism & Toxicology
- Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously
- (2018) Jie Zang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones
- (2018) Nikolas Tim Martin et al. MOLECULAR THERAPY
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hypoxia driven glycation: Mechanisms and therapeutic opportunities
- (2018) Mohammad Imran Khan et al. SEMINARS IN CANCER BIOLOGY
- Targeting VEGF/VEGFR to Modulate Antitumor Immunity
- (2018) Ju Yang et al. Frontiers in Immunology
- Structure-Based Drug Design Strategies and Challenges
- (2018) Xin Wang et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Exploration of novel pyrrolo[2,1-f][1,2,4]triazine derivatives with improved anticancer efficacy as dual inhibitors of c-Met/VEGFR-2
- (2018) Wei Shi et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Computational approaches for the design of mosquito repellent chemicals
- (2018) Subhash C. Basak et al. CURRENT MEDICINAL CHEMISTRY
- ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
- (2018) Tim H. Holmström et al. MOLECULAR CANCER THERAPEUTICS
- Novel SERMs based on 3-aryl-4-aryloxy-2H-chromen-2-one skeleton - A possible way to dual ERα/VEGFR-2 ligands for treatment of breast cancer
- (2017) Guoshun Luo et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Synthesis and biological evaluation of novel 6,11-dihydro-5 H -benzo[e]pyrimido- [5,4- b ][1,4]diazepine derivatives as potential c-Met inhibitors
- (2017) Daowei Huang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors
- (2017) Lin Xiao Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Recent advances of pyrrolopyridines derivatives: a patent and literature review
- (2017) Mohammed I. El-Gamal et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Cooperative oncogenic effect and cell signaling crosstalk of co-occurring HER2 and mutant PIK3CA in mammary epithelial cells
- (2017) Lun Dong et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies
- (2017) Rahul Aggarwal et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines
- (2017) Yanmin Zhang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design and Discovery of Quinazoline- and Thiourea-Containing Sorafenib Analogs as EGFR and VEGFR-2 Dual TK Inhibitors
- (2017) Shaofeng Sun et al. MOLECULES
- Bisarylureas Based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold as Novel Pan-RAF Inhibitors with Potent Anti-Proliferative Activities: Structure-Based Design, Synthesis, Biological Evaluation and Molecular Modelling Studies
- (2017) Yu Fu et al. MOLECULES
- Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy
- (2017) Hao Chen et al. MOLECULES
- Systemic Therapy for Metastatic Renal-Cell Carcinoma
- (2017) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting VEGFR and FGFR in head and neck squamous cell carcinoma in vitro
- (2017) Roman C. Brands et al. ONCOLOGY REPORTS
- Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas
- (2017) Robert Roskoski PHARMACOLOGICAL RESEARCH
- The role and significance of VEGFR2+ regulatory T cells in tumor immunity
- (2017) Panrong Zhu et al. OncoTargets and Therapy
- A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status
- (2017) Benjamin Izar et al. Cancer Medicine
- Synthesis of 4-Anilinoquinazoline-Derivative Dual Kinase Inhibitors Targeting EGFR and VEGFR-2
- (2017) Keuk Chan Bang et al. BULLETIN OF THE KOREAN CHEMICAL SOCIETY
- Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors
- (2016) Wufu Zhu et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Design, synthesis, and docking studies of phenylpicolinamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors
- (2016) Wufu Zhu et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Design, synthesis and biological evaluation of 4-aminopyrimidine-5-cabaldehyde oximes as dual inhibitors of c-Met and VEGFR-2
- (2016) Hao Qiang et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program
- (2016) Markus Moehler et al. BMC CANCER
- Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial
- (2016) A. X. Zhu et al. CLINICAL CANCER RESEARCH
- Pyridine Based Antitumour Compounds Acting at the Colchicine Site
- (2016) R. Álvarez et al. CURRENT MEDICINAL CHEMISTRY
- Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect
- (2016) Leilei Shi et al. CURRENT MEDICINAL CHEMISTRY
- Design, synthesis and evaluation of 6-aryl-indenoisoquinolone derivatives dual targeting ERα and VEGFR-2 as anti-breast cancer agents
- (2016) Zhichao Tang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing 1,2,4-triazolone moiety as c-Met kinase inhibitors
- (2016) Ju Liu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC
- (2016) Fan-Wei Peng et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
- (2016) MASARU KATOH INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Discovery of 3-(5′-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation
- (2016) Wei Yan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
- (2016) Marcia S Brose et al. LANCET ONCOLOGY
- Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology
- (2015) Brendan Frett et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation
- (2015) S. Fu et al. ANNALS OF ONCOLOGY
- The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents
- (2015) Xin Zhang et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Drug repositioning and repurposing: terminology and definitions in literature
- (2015) Joris Langedijk et al. DRUG DISCOVERY TODAY
- Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response
- (2015) M. Cesca et al. MOLECULAR CANCER THERAPEUTICS
- Molecular Docking and Structure-Based Drug Design Strategies
- (2015) Leonardo Ferreira et al. MOLECULES
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
- (2015) Martin Schlumberger et al. NEW ENGLAND JOURNAL OF MEDICINE
- The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents
- (2014) Xin Zhang et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Synthesis and biological evaluation of 2,3-diaryl isoquinolinone derivatives as anti-breast cancer agents targeting ERα and VEGFR-2
- (2014) Zhichao Tang et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Pazopanib and HDAC inhibitors interact to kill sarcoma cells
- (2014) Seyedmehrad Tavallai et al. CANCER BIOLOGY & THERAPY
- PIM kinases: an overview in tumors and recent advances in pancreatic cancer
- (2014) Jianwei Xu et al. Future Oncology
- Back Pocket Flexibility Provides Group II p21-Activated Kinase (PAK) Selectivity for Type I 1/2 Kinase Inhibitors
- (2014) Steven T. Staben et al. JOURNAL OF MEDICINAL CHEMISTRY
- Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
- (2014) Joyce F Liu et al. LANCET ONCOLOGY
- Discovery of Antitubulin Agents with Antiangiogenic Activity as Single Entities with Multitarget Chemotherapy Potential
- (2014) Aleem Gangjee et al. ACS Medicinal Chemistry Letters
- Recent progress in the identification of BRAF inhibitors as anti-cancer agents
- (2013) Hala Bakr El-Nassan EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer
- (2013) Daniel Chan et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Microtubules Coordinate VEGFR2 Signaling and Sorting
- (2013) Catherine Czeisler et al. PLoS One
- Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer
- (2012) Richard H. De Boer et al. BREAST CANCER RESEARCH AND TREATMENT
- E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models
- (2011) Ezia Bello et al. CANCER RESEARCH
- Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy
- (2011) Yasufumi Sato CANCER SCIENCE
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacophore modeling and applications in drug discovery: challenges and recent advances
- (2010) Sheng-Yong Yang DRUG DISCOVERY TODAY
- Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: A potential clinical application of angiogenesis inhibitors
- (2010) Roshani R. Patel et al. EUROPEAN JOURNAL OF CANCER
- Quantification and cell-to-cell variation of vascular endothelial growth factor receptors
- (2010) P.I. Imoukhuede et al. EXPERIMENTAL CELL RESEARCH
- AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo
- (2010) Mylin A. Torres et al. INVESTIGATIONAL NEW DRUGS
- Discovery of Dual VEGFR-2 and Tubulin Inhibitors with in Vivo Efficacy
- (2010) Eugene L. Piatnitski Chekler et al. ACS Medicinal Chemistry Letters
- E7050: A dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models
- (2009) Takayuki Nakagawa et al. CANCER SCIENCE
- Discovery of a Potent, Selective, and Orally Bioavailable c-Met Inhibitor: 1-(2-Hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458)
- (2008) Longbin Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Brivanib Alaninate ((S)-((R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), A Novel Prodrug of Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinase Inhibitor (BMS-540215)
- (2008) Zhen-wei Cai et al. JOURNAL OF MEDICINAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More